Investments
158Portfolio Exits
33Funds
5Partners & Customers
1Service Providers
1
Want to inform investors similar to Elaia Partners about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Research containing Elaia Partners
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Elaia Partners in 1 CB Insights research brief, most recently on Sep 24, 2021.
Latest Elaia Partners News
Oct 17, 2022
Mablink Bioscience (Mablink), a Lyon-based biotechnology company, has raised €31M in a Series A funding round led by Sofinnova Partners and Mérieux Equity Partners, with participation from existing investors. Existing shareholders, Elaia Partners, UI-Investissement / Pertinence Invest 2 (advised by Mérieux Equity Partners), Sham Innovation Santé (advised by Turenne Capital), Fondation Fournier-Majoie, Simba Santé (Angelor) and Crédit Agricole Création also participated in the funding round. The capital will allow Mablink to become clinical-stage biotech by bringing its lead candidate, MBK-103, into clinical development to treat solid tumors, notably ovarian cancer. At the same time, Mablink will build a pipeline of ADCs for solid tumors. As part of the funding round, Dr. Calenda and Mr. Seghezzi join Mablink’s Board of Directors. “We are very proud to be joined by such experienced investors,” says Jean-Guillaume Lafay, Chief Executive Officer and co-founder of Mablink. “They bring the necessary funds but also the expertise and network that will be critical for the success of Mablink in bringing its first ADC to the clinic. We also thank our historical investors who decided to reinvest in this round.” Developing antibody-drug conjugates Mablink’s technology is based on a unique structure of chemical links (called “linkers”) placed between an antibody and any chosen cytotoxic molecule to be delivered into tumor cells. The linkers mask the cytotoxic molecule, which provides a “stealthy” property to Mablink’s ADCs, conferring two highly desirable pharmacological properties. First, it enables ADCs to stay longer in the body and gives them more time to destroy tumor cells. Second, these stealth ADCs have greatly improved tolerability. Consequently, it results in a 10-fold increase in the therapeutic index observed in animal models, a potentially game-changing factor for future clinical successes in the ADC space. “Mablink offers a complete solution that tackles the challenges currently limiting the development of ADCs,” says Graziano Seghezzi, Managing Partner at Sofinnova Partners. “With its “masking” technology, we have the potential to build a pipeline of products for patients without real treatment options today. We look forward to working with Jean-Guillaume and his team to transform Mablink into a global ADC player.” Valérie Calenda, the Managing Partner of Mérieux Equity Partners, says, “Merieux Equity Partners was attracted by the project at its inception in 2019 and decided to support it through its industrial accelerator M2Care before advising UI Investment and Pertinence Invest 2 to participate in the seed round. Since then, the quality of the team and progress reinforced our conviction that this platform can bring millions of patients safer and more potent ADCs thanks to an improved therapeutic window. As a result, we are delighted to continue supporting MabLink by co-leading this Series A financing with our venture fund OMX Europe.” “After a €4M Seed funding a year ago, Mablink enters a new era. We are particularly proud of the success of this Series A funding, which will increase exponentially the capacities and investments of the company in research and development, the consolidation of its pipeline, as well as the hiring of seasoned profiles,” says Florian Denis, Investment Director at Elaia, on behalf of the Mablink’s historic investors.
Elaia Partners Investments
158 Investments
Elaia Partners has made 158 investments. Their latest investment was in Giskard as part of their Seed VC on December 12, 2022.

Elaia Partners Investments Activity

Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
12/15/2022 | Seed VC | Giskard | $1.6M | Yes | 1 | |
12/1/2022 | Seed VC | Arsen | $2.65M | Yes | Elaia Partners, and LeFonds | 1 |
11/18/2022 | Seed VC - II | Spectral | $2.1M | No | Elaia Partners, and Go Capital | 1 |
11/10/2022 | Series A | |||||
10/25/2022 | Series A |
Date | 12/15/2022 | 12/1/2022 | 11/18/2022 | 11/10/2022 | 10/25/2022 |
---|---|---|---|---|---|
Round | Seed VC | Seed VC | Seed VC - II | Series A | Series A |
Company | Giskard | Arsen | Spectral | ||
Amount | $1.6M | $2.65M | $2.1M | ||
New? | Yes | Yes | No | ||
Co-Investors | Elaia Partners, and LeFonds | Elaia Partners, and Go Capital | |||
Sources | 1 | 1 | 1 |
Elaia Partners Portfolio Exits
33 Portfolio Exits
Elaia Partners has 33 portfolio exits. Their latest portfolio exit was UWINLOC on January 04, 2023.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
1/4/2023 | Acquired | 1 | |||
10/4/2022 | Corporate Majority | 7 | |||
9/7/2022 | Acquired | 19 | |||
Date | 1/4/2023 | 10/4/2022 | 9/7/2022 | ||
---|---|---|---|---|---|
Exit | Acquired | Corporate Majority | Acquired | ||
Companies | |||||
Valuation | |||||
Acquirer | |||||
Sources | 1 | 7 | 19 |
Elaia Partners Fund History
5 Fund Histories
Elaia Partners has 5 funds, including Elaia Alpha II.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
---|---|---|---|---|---|
7/11/2022 | Elaia Alpha II | $77.29M | |||
5/23/2019 | PSL Innovation Fund | ||||
5/3/2017 | Elaia Delta Fund | ||||
10/31/2012 | ELAIA Alpha | ||||
12/31/2004 | ELAIA Ventures |
Closing Date | 7/11/2022 | 5/23/2019 | 5/3/2017 | 10/31/2012 | 12/31/2004 |
---|---|---|---|---|---|
Fund | Elaia Alpha II | PSL Innovation Fund | Elaia Delta Fund | ELAIA Alpha | ELAIA Ventures |
Fund Type | |||||
Status | |||||
Amount | $77.29M | ||||
Sources |
Elaia Partners Partners & Customers
1 Partners and customers
Elaia Partners has 1 strategic partners and customers. Elaia Partners recently partnered with IT-Translation on November 11, 2017.
Date | Type | Business Partner | Country | News Snippet | Sources |
---|---|---|---|---|---|
11/16/2017 | Partner | France | IT-TRANSLATION and Elaia Partners combine their talents for the future – Elaia Partners This partnership between Elaia Partners and IT-Translation is a natural evolution from previous colaborations between the teams . | 1 |
Date | 11/16/2017 |
---|---|
Type | Partner |
Business Partner | |
Country | France |
News Snippet | IT-TRANSLATION and Elaia Partners combine their talents for the future – Elaia Partners This partnership between Elaia Partners and IT-Translation is a natural evolution from previous colaborations between the teams . |
Sources | 1 |
Elaia Partners Service Providers
1 Service Provider
Elaia Partners has 1 service provider relationship
Service Provider | Associated Rounds | Provider Type | Service Type |
---|---|---|---|
Accounting Firm | General Counsel |
Service Provider | |
---|---|
Associated Rounds | |
Provider Type | Accounting Firm |
Service Type | General Counsel |
Partnership data by VentureSource
Elaia Partners Team
1 Team Member
Elaia Partners has 1 team member, including former Founder, Maryline Kulawik.
Name | Work History | Title | Status |
---|---|---|---|
Maryline Kulawik | Galileo Partners, and BNP Paribas | Founder | Former |
Name | Maryline Kulawik |
---|---|
Work History | Galileo Partners, and BNP Paribas |
Title | Founder |
Status | Former |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.